COVID-19 measures – Isotopia Molecular Imaging

Isotopia Molecular Imaging and Molecular Targeting Technologies have signed a clinical supply agreement for Lu177 n.c.a.

Petach Tikva, Israel, 10th March 2021 – Isotopia Molecular Imaging is pleased to announce that it has begun a collaboration with Molecular Targeting Technologies, Inc. (MTTI), a clinical stage biopharmaceutical company, for the supply of the medical radioisotope no-carrier-added 177Lu (n.c.a. 177Lu) to support clinical development of its targeted radiotherapeutic products. 

Molecular Targeting Technologies, Inc. (MTTI) has received an exclusive worldwide license from the National Institutes of Health to commercialize targeted radiotherapeutics covered by their Evans Blue (EB) platform technology patents.177Lu- EBTATE, which targets somatostatin receptors type 2 (SSTR2) in a variety of neuroendocrine tumors (NETs), and 177Lu-EBRGD for integrin expressing cancers in Glioblastoma multiforme (GBM) and Non-Small Cell Lung cancer (NSCLC), are the first products in development. In this breakthrough, EB is affixed to the targeting peptide radiopharmaceutical.

That combination binds reversibly to circulating serum albumin, enhancing radiotherapeutic circulation half-life and delivering higher accumulation to targeted tumors.

177Lu is a beta-emitting radiopharmaceutical precursor with a half-life of 6.7 days and maximum energy of 0.5 MeV, corresponding to a maximum soft-tissue penetration of approximately 1 mm from its binding site. 177Lu is used in Precision Oncology for Targeted Radionuclide Therapy. It, precisely, destroys the tumor when bound to disease-specific, targeting therapeutics. Isotopia has developed a unique, stable, consistent and reliable GMP method to produce a highly pure form of 177Lu. n.c.a.  Isotopia’s 177Lu contains no metastable 177mLu, eliminating cost intensive clinical waste management.

Isotopia’s CEO Dr. Eli Shalom stated, “Our strategy is to be partner to every leading pharmaceutical company developing Lu-177 n.c.a based products, supporting them from clinical trials through commercial sale. We are committed to produce 52 weeks per year, ensuring supply through long-term contracts. We’re patient-centric. Our two years of robust, reliable and flawless production enhances patient confidence. MTTI is a remarkable company which advances their vision for the development of new radiotherapeutics and Isotopia is proud to be part of it.”

Theranostics - Isotopia